Mental Health
TOOLBOX
Filter
64
Featured
Language
Document type
No document type
42
Training Material
10
Manuals
6
Fact sheets
3
Guidelines
2
Resource Platforms
1
Countries / Regions
Western and Central Europe
2
Russia
2
Authors & Publishers
World Health Organization WHO
31
World Health Organization
24
WHO
22
World Health Organisation (WHO)
3
World Health Organization (WHO)
3
World Health Organitarion
2
World Health Organization WHO, UNICEF
1
World Health Organization, UNHCR
1
Ніко Кларк, Тарун Дуа, Александра Фляйшманн et al.
1
Publication Years
Category
Mobile Training Tools & Apps
1
Training Manuals
1
Toolboxes
Scoping Question: For adults and children living with HIV, which antiepileptic medications (such as phenobarbital, phenytoin, carbamazepine or valproic acid) produce benefits and/or harms when compared to a placebo or controls?
[Updated 2015] Scoping Question: In adults with acute convulsive seizures in first-level care or in the community (when no IV access is available), which antiepileptic medications produce benefits and/or harm when compared to comparator?
В этом разделе «Руководства mhGAP по принятию мер в отношении психических и неврологических расстройств» приведены рекомендации по оценке и оказанию помощи при ост... more
Q5.SCOPING QUESTION: In individuals with psychotic disorders (including schizophrenia) who require long-term antipsychotic treatment, what is the safety and role of depot antipsychotic medication?
Q7: In individuals with bipolar mania, are a) antipsychotics, b) mood stabilizers (lithium carbonate, valproate, and carbamazepine) effective and safe
What can you expect? As a future facilitator your role will be to learn about the structure of mhGAP-IG, how to teach the materials and utilize opportunities to prastice facilitation and supervision skills. As a supervisor your role will be to serve as a point of reference for non-specialized heal... more
Q 1: Are antidepressants (Tricyclic Antidepressants (TCA) and Selective Serotonin Reuptake Inhibitors (SSRI)) better (more effective than/as safe as) than treatment as usual (placebo) in adults with depressive episode/disorder?
Q 3: Is brief, structured psychological treatment in non-specialist health care settings better (more effective than/as safe as) than treatment as usual in people with depressive episode/disorder?
Q 4: Is behavioural activation better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?brief, structured psychological treatment in non-specialist health care settings better (more effective than/as safe as) than treatment as usual in people with de... more
Q14. SCOPING QUESTION: In adults with psychotic disorders (including schizophrenia), what is the comparative effectiveness and safety of second-generation antipsychotic medications?
Q3: In individuals with a first psychotic episode with full remission, how long should antipsychotic drug treatment be continued after remission in order to allow for the best outcomes?
Q1: In individuals with psychotic disorders (including schizophrenia), are antipsychotic drugs safe and effective?
Q6: In individuals with psychotic disorders (including schizophrenia) who require long term antipsychotic treatment, are anticholinergic medications more effective in preventing or reducing extrapyramidal side-effects and/or improving treatment adherence than placebo/treatment as usual?
Q6: Is advice on physical activity better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder with inactive lifestyles
Q9. In adults and children with convulsive epilepsy in remission, when should treatment be discontinued?
Q3: Can febrile seizures (simple or complex) be managed at first or second level care by non-specialist health care providers in low and middle income country settings? What is the role of diagnostic tests in the management of febrile seizures by non-specialists in low and middle income settings? Fo... more
Q5: What is the added advantage of doing an electroencephalography (EEG) in people with convulsive epilepsy in non- specialist settings in low and middle income countries?
Q 10: In adults and children with epilepsy, which psychological interventions used as adjunctive therapies with antiepileptic drugs when compared to placebo/comparator produce benefits/harm in specified outcomes?
Q6: What is the added advantage of doing neuroimaging in people with convulsive epilepsy in non-specialist settings in low and middle income countries?
Q4: Can convulsive epilepsy be diagnosed at first level care by a non-specialist health care provider in low and middle income country settings?